Results 121 to 130 of about 4,011,812 (307)

Liquid biopsy‐based diagnostic evaluation of hypermethylated CpG sites for ovarian cancer diagnosis

Molecular Oncology, EarlyView.
This schematic outlines the workflow from biomarker identification to duplex MethyLight assay validation for epithelial ovarian cancer diagnosis using cfDNA‐based liquid biopsy. Initial screening of hypermethylated CpG candidates (cg02957270, cg10061138 cg00480298, COL2A1) was performed in tissue using ARMS‐PCR, COBRA, qPCR and image analysis. Selected
Deepa Bisht, Sameer Gupta, Amrita Chaurasia, Manisha Sachan   +3 more
wiley   +1 more source

In This Issue, Volume 6, Issue 6 [PDF]

ACS Chemical Neuroscience, 2015
openaire   +3 more sources

VOLUME 6, NUMBER 1

Independent Journal of Management & Production, 2015
Rodrigues, Paulo Cesar Chagas, Louzada, Carlos Antonio Pizarro   +1 more
openaire   +3 more sources

Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola, Yasmine Illi, Anna Bircher, Marijn Wilmink, Rachele F. Malagutti, Solenn Ottié, Cordelia Schuler, Pedro A. Ruiz, Cheryl de Vallière, Klaus Seuwen, Gerhard Rogler, Martin Hausmann   +11 more
wiley   +1 more source

Corrigendum to 'Plasma proteomic profiles of patients with atopic dermatitis with moderate-to-severe pruritus treated with a single dose of nemolizumab' JID Innovations, Volume 6, Issue 3, May 2026, 100457. [PDF]

JID Innov
Nakajima S, Iizuka H, Taira K, Tanaka K, Hashimoto K, Kaneda N, Iwasaki K, Takafuji T, Yamada Y, Kabashima K.   +9 more
europepmc   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

A Multi-Faceted Issue to Complete Volume 6. [PDF]

Bioelectricity
Levin M, Djamgoz MBA.
europepmc   +1 more source

Corrigendum to "The systematic risk estimation models: A different perspective" [Volume 6, Issue 2 (February 2020) e03371]. [PDF]

Heliyon, 2023
Duc Pham C, Phuoc LT.
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source